Statins: lower LDL cholesterol, stabilise plaque and prevent cardiovascular events
Statins inhibit hepatic HMG-CoA reductase. The fall in hepatic cholesterol up-regulates LDL receptors, clearing more LDL cholesterol from the blood. Their value is not simply “a better lipid result”: in the right patient they lower the risk of myocardial infarction, ischaemic stroke and cardiovascular death. They are foundational therapy for established atherosclerotic cardiovascular disease (ASCVD) and are selected for primary prevention according to total risk.
Learning outcomes
Explain lipoprotein transport and the statin mechanism; classify statin intensity; choose appropriate prevention contexts; identify adverse effects and interactions; investigate muscle symptoms safely; and counsel patients on adherence, pregnancy and lifestyle.
1. Start with the lipid map
| Particle | Main cargo / origin | Clinical meaning |
|---|---|---|
| Chylomicron | Dietary triglyceride from intestine | Very high triglycerides raise pancreatitis risk; chylomicron remnants carry cholesterol back to the liver. |
| VLDL → IDL | Triglyceride-rich particles made by liver | VLDL is progressively triglyceride-depleted to IDL, then LDL. |
| LDL | Cholesterol delivered to peripheral tissues | The main atherogenic target in most patients. Cumulative LDL exposure drives plaque formation. |
| HDL | Reverse cholesterol transport | Low HDL can mark risk, but drugs are not prescribed merely to “raise HDL.” Treat the whole risk profile. |
| Lipoprotein(a) | Genetically determined LDL-like particle | A risk enhancer; consider measurement where guidance/resources support it, especially with premature ASCVD or family history. |
Atherosclerosis in one line
ApoB-containing particles—especially LDL—enter and are retained in the arterial wall. Inflammation, oxidation, foam-cell formation and fibrous plaque follow. Plaque rupture with thrombosis produces acute MI or ischaemic stroke. Statins lower circulating LDL and also improve plaque stability.
2. Mechanism of action: why blocking synthesis lowers blood LDL
1. Competitive inhibition
Statins competitively and reversibly inhibit HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate in cholesterol synthesis.
2. Less hepatic cholesterol
Hepatocytes sense a lower intracellular cholesterol pool.
3. More LDL receptors
The liver up-regulates LDL receptors on its surface and removes more circulating LDL particles.
4. Clinical benefit
LDL-C falls substantially; triglycerides often fall modestly and HDL may rise slightly. Event reduction follows sustained use in appropriate-risk patients.
Exam distinction: statins do not “dissolve an acute clot.” They reduce atherosclerotic risk and are central to secondary prevention after ACS/MI, alongside antiplatelet therapy, BP/diabetes management, smoking cessation, rehabilitation and revascularisation when indicated.
3. The drugs: potency and intensity
| Intensity (approximate LDL-C reduction) | Common examples | Use concept |
|---|---|---|
| High intensity (≥50%) | Atorvastatin 40–80 mg; rosuvastatin 20–40 mg | Usually preferred in many adults with clinical ASCVD if tolerated; use current local guidance and product labelling. |
| Moderate intensity (30–49%) | Atorvastatin 10–20 mg; rosuvastatin 5–10 mg; simvastatin 20–40 mg; pravastatin 40–80 mg | Chosen when risk/age/comorbidity or tolerance makes high intensity unsuitable, and in many primary-prevention plans. |
| Low intensity (<30%) | Simvastatin 10 mg; pravastatin 10–20 mg | Less common when meaningful LDL reduction is required; consider only within an individualised plan. |
Important pharmacokinetic comparison
- Atorvastatin, simvastatin and lovastatin: important CYP3A4 interaction potential.
- Rosuvastatin and pravastatin: less CYP3A4 dependence, but still have clinically relevant transporter/drug interactions.
- Simvastatin: has more dose-related interaction restrictions; check the specific co-prescription rather than assuming all statins behave alike.
4. Indications: primary versus secondary prevention
| Situation | Statin role | Clinical reasoning |
|---|---|---|
| Established ASCVD prior MI/ACS, angina with coronary disease, ischaemic stroke/TIA, symptomatic peripheral arterial disease |
Secondary prevention—usually a maximally tolerated high-intensity statin unless contraindicated. | Risk of recurrent event is high; treatment aims for large LDL reduction and addition of non-statin therapy may be considered if response is inadequate. |
| Diabetes mellitus | Risk-based primary prevention; intensity depends on age, risk factors, duration/organ damage and guideline assessment. | Diabetes substantially increases ASCVD risk, but treatment should remain individualised. |
| Familial hypercholesterolaemia (FH) | Early high-potency therapy and specialist pathway. | Consider very high baseline LDL-C, family cascade screening, and need for combination treatment. |
| No established ASCVD | Primary prevention after formal cardiovascular-risk assessment and shared decision-making. | Do not prescribe from a total-cholesterol number alone. Include BP, smoking, diabetes, kidney disease, age, family history and local risk tool. |
| Severe hypertriglyceridaemia | Statins may address ASCVD risk but are not the sole urgent strategy. | Identify secondary causes and treat pancreatitis risk with appropriate diet/diabetes/alcohol review and triglyceride-directed therapy where indicated. |
Before starting: look for secondary causes and risk amplifiers
Check for hypothyroidism, uncontrolled diabetes, nephrotic syndrome/CKD, excess alcohol, obesity, cholestatic liver disease and relevant drugs. Untreated hypothyroidism can both worsen lipids and increase muscle-toxicity risk. Obtain a careful family history of premature ASCVD and extreme cholesterol because it may signal FH.
5. Baseline assessment and follow-up
| When | Assess | Why |
|---|---|---|
| Before therapy | Lipid profile; ASCVD risk; BP, glucose/diabetes status; adherence barriers; interacting medicines; alcohol/liver history; pregnancy/breastfeeding status where relevant. | Defines indication, expected response and safety risks. |
| Baseline tests | ALT/liver enzymes before initiation; HbA1c/glucose when clinically indicated; TSH if hypothyroidism is suspected. Baseline CK is not routine for everyone, but is reasonable with prior muscle disease/symptoms, interacting drugs, renal impairment or high risk. | Allows rational interpretation of later abnormalities and avoids missing reversible causes. |
| After starting or dose change | Repeat lipid profile at the interval specified by local guidance (often 4–12 weeks) to assess adherence and percentage LDL response. | Do not label treatment a failure until adherence, dose, secondary causes and interactions are reviewed. |
| Symptom-triggered review | CK for significant unexplained muscle symptoms; liver enzymes if symptoms/signs of liver injury; renal function and urine assessment if severe muscle injury is suspected. | Routine serial CK and LFT “screening” in a well patient is usually not required; investigate clinically meaningful symptoms. |
6. Adverse effects: separate common symptoms from rare emergencies
Muscle symptoms
Myalgia (pain/aches without major CK rise) is reported commonly. Assess timing, bilateral proximal pattern, exertion, thyroid disease, vitamin deficiency, infection and interacting drugs; not every ache is caused by the statin.
Myopathy / rhabdomyolysis
Rare but serious. Severe pain, weakness, marked CK elevation, dark/tea-coloured urine or reduced urine output demand urgent review and stopping the suspected drug.
Hepatic effects
Small transaminase rises can occur. Serious liver injury is rare; jaundice, dark urine, persistent nausea, right-upper-quadrant pain or marked fatigue require evaluation.
Other
Dyspepsia, headache and a small increase in glucose/diabetes risk in susceptible people may occur. In indicated patients, cardiovascular benefit generally outweighs this risk.
Muscle-symptom algorithm
- Ask about onset relative to treatment/dose change; examine severity, weakness, hydration and urine colour.
- Check for interacting medicines, strenuous exercise, alcohol, hypothyroidism, renal/hepatic disease and infection.
- Measure CK when symptoms are clinically significant; evaluate renal function/urinalysis urgently if rhabdomyolysis is possible.
- With severe symptoms or marked CK elevation, stop the statin and urgently manage as possible muscle injury.
- Once resolved, do not abandon prevention automatically: the prescriber may rechallenge at a lower dose, use a different statin, intermittent specialist-directed strategy, or add non-statin LDL-lowering therapy.
Never tell a patient with dark urine and weakness merely to “wait and see.” Consider rhabdomyolysis and acute kidney injury.
7. Interactions: preventable causes of harm
| Interaction / factor | Effect | Safe action |
|---|---|---|
| Gemfibrozil | Substantially increases risk of statin-associated myopathy/rhabdomyolysis. | Avoid combination where possible. If triglyceride therapy is needed, use a deliberate specialist/local-guideline plan; do not casually add a fibrate. |
| Macrolides, azole antifungals, HIV/HCV antivirals, cyclosporine | Several strongly raise exposure to CYP3A4-metabolised statins. | Check the individual medicine interaction database/label. Hold, adjust or choose an alternative statin only under an appropriate prescriber plan. |
| Grapefruit products | Can increase levels of some CYP3A4 statins, especially simvastatin/lovastatin. | Avoid large amounts; give medicine-specific advice. |
| Other fibrates / niacin | May increase muscle toxicity. | Use only when the indication is strong and monitoring is planned. |
| Warfarin | Some statins can alter anticoagulant effect. | Check INR more closely after initiation or dose change as directed. |
| Rifampicin and enzyme inducers | May reduce exposure/effect of selected statins. | Review choice and lipid response rather than assuming therapeutic failure. |
8. Liver disease, pregnancy and breastfeeding
- Acute liver failure or decompensated cirrhosis: atorvastatin is contraindicated; review the specific statin label and specialist advice in chronic liver disease.
- Unexplained persistent significant transaminase elevation: investigate; do not simply increase the dose.
- Pregnancy: lipid-lowering therapy is generally stopped when pregnancy is recognised because treatment of usual hypercholesterolaemia can usually pause and fetal safety is a concern. Rare very-high-risk situations require specialist risk–benefit decision-making—do not apply a blanket statement without assessment.
- Breastfeeding: avoid statins unless a specialist has made a specific plan; check current product information.
9. What if LDL remains above goal or the patient cannot tolerate a statin?
First verify adherence, dose, diet, secondary causes and interactions. Then use the maximally tolerated statin—not necessarily the highest theoretical dose. Depending on risk, LDL level, availability and local guideline, add or substitute:
- Ezetimibe: reduces intestinal cholesterol absorption; a common first add-on.
- PCSK9-directed therapy: potent LDL reduction for selected very-high-risk or FH patients; access/cost often limit use.
- Bempedoic acid: an oral non-statin option in selected patients, especially true statin intolerance, following guideline/availability assessment.
- Triglyceride-focused therapy: follows the triglyceride pattern and pancreatitis risk; it is not interchangeable with LDL-focused secondary prevention.
Red yeast rice and unregulated supplements are not a safe substitute for an evidence-based statin plan: potency and contaminants vary, and statin-like adverse effects/interactions can still occur.
10. Clinical counselling and adherence
Five messages every patient should leave with
- Purpose: “This reduces your future heart attack and stroke risk; you may feel no immediate difference because prevention is the point.”
- How to take it: take once daily exactly as prescribed. Atorvastatin/rosuvastatin may generally be taken at a convenient consistent time; shorter-acting statins are often scheduled in the evening. Follow the specific product directions.
- Do not stop silently: muscle pain, weakness, jaundice or troublesome effects need review; stopping without an alternative can remove important protection.
- Interaction check: tell clinicians and pharmacists before starting antibiotics, antifungals, antivirals, supplements or fibrates.
- Lifestyle remains treatment: heart-healthy diet, smoking cessation, physical activity, weight/BP/diabetes control and medication adherence act together; statin therapy is not permission to ignore them.
11. Applied cases
Case 1: post-MI discharge
A 58-year-old with ACS is discharged on atorvastatin. The key point is secondary prevention: high-intensity statin therapy is usually used if tolerated, with lipid follow-up, adherence assessment and wider post-MI prevention. It is not prescribed because “cholesterol is high today” alone.
Case 2: thigh pain after clarithromycin
A patient taking simvastatin develops bilateral thigh pain after receiving clarithromycin. Suspect a pharmacokinetic interaction. Assess severity and CK as indicated, stop/hold the relevant drug under clinical direction, and review the antibiotic/statin plan urgently—do not dismiss it as ordinary ageing.
Case 3: diabetes plus high LDL, no previous event
Use formal cardiovascular-risk assessment, lipid profile, BP, renal status, smoking and duration/complications of diabetes. Select intensity according to current guideline and patient factors, then check response and adherence. This is primary prevention, not a one-size-fits-all dose.
12. High-yield revision box
- Target enzyme: HMG-CoA reductase.
- Main LDL-lowering mechanism: reduced hepatic cholesterol → increased hepatic LDL receptors → increased LDL clearance.
- High intensity: atorvastatin 40–80 mg; rosuvastatin 20–40 mg (typical examples).
- Classic serious toxicity: rhabdomyolysis—pain/weakness + dark urine/renal injury risk.
- Important interaction: gemfibrozil and strong CYP3A4 inhibitors can raise myopathy risk.
- Before blaming the statin: check thyroid disease, exertion, alcohol, renal/hepatic dysfunction and interacting drugs.
- After MI: statin is secondary prevention and should be paired with comprehensive cardiovascular care.
References and further study
- Lyndon Woytuck. Statins. Supplied SlideShare teaching resource, reviewed and updated for this curriculum lesson.
- 2026 ACC/AHA/Multisociety Guideline for the Management of Dyslipidemia.
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Chronic Coronary Disease.
- 2025 Focused Update of the ESC/EAS Guidelines for the Management of Dyslipidaemias.
- DailyMed. Atorvastatin prescribing information (myopathy, hepatic safety, pregnancy and interactions).
Educational note: This is an undergraduate revision resource, not an individual prescription. Statin choice, dose, LDL target, monitoring and use in pregnancy/liver disease must follow current local protocol, product information and a qualified prescriber’s plan.
